Reviewer's report

**Title:** Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs AEZS 108 and AEZS 125

**Version:** 2  
**Date:** 20 March 2014

**Reviewer:** Sham Kakar

**Reviewer's report:**

**Major:**

The manuscript is interested for TNBC. Using the AN152, authors have published several manuscripts using different cell lines and various cancers. No new mechanisms or pathways have been demonstrated which could differentiate TNBC from estrogen positive or Her2 positive cell lines. No RT/PCR data is provided in the manuscript to show expression of LHRH receptor. In addition, no pharmacokinetics or pharmodynamics, and accumulation of drug in heart as well as in other tissues is demonstrated. No toxicity data is included showing if the dose used in mice is safe and does not cause abnormal heart function. It may be more appropriate to use mouse mammary pads to develop breast tumor than s.c., since it will mimic the tumor micro-environment.

**Minor:**

There are some typographical errors which need attention.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

No conflict of interest